IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.

Revenue
+9.86%
EPS
+17.3%
Free cash flow
+17.6%
Total debt
−28.6%

Quarter to September 2026, against a year earlier

669.67 1.04 −0.16%
Market cap
$52.8B
P/E
44.8×
Fwd P/E
37.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a

IDEXX Laboratories, Inc. 10-K filed Feb 20, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:09 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business, against the 10-K filed Feb 21, 2025: 2 added · 6 removed · 68 modified

  1. Modified · COMPANY OVERVIEW

    IDEXX was incorporated in Delaware in 1983. We develop, manufacture, and distribute products and provide services primarily for the companion animal veterinary,; livestock and , poultry, and dairy; and water testing industries. We also provide manufacture and sell human medical point-of-care and laboratory diagnosticsdiagnostic products. Our primary products and services are: